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a  b  s  t  r  a  c  t
Tuberculosis (TB) is still considered a major global public health problem in the world
and there is a concern about the worldwide increase of drug-resistance (DR). This paper
describes the analysis of three Mycobacterium tuberculosis isolates from a single patient
collected over a long treatment period of time. DR was initially investigated through pheno-
typic testing, followed by line probe assays (LPAs) and whole genome sequencing (WGS). It
presents an intriguing situation where a multidrug-resistant (MDR-) TB case was diagnosed
and  treated based only on late phenotypic drug susceptibility testing of isolate 1. During
the  treatment, another two isolates were cultivated: isolate 2, nine months after starting
MDR-TB treatment; and isolate 3, cultivated ﬁve months later, during regular use of anti-TB
drugs. These two isolates were evaluated using molecular LPA and WGS,  retrospectively. All
mutations detected by LPA were also detected in the WGS,  including conversion from ﬂuo-
roquinolones susceptibility to resistance from isolate 2 to isolate 3. WGS  showed additional
mutations, including some which may confer resistance to other drugs not tested (ter-izidone/cycloserine) and mutations with no correspondent resistance in drug susceptibility
testing (streptomycin and second-line injectable drugs).
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
its causative agent could be the key to the development ofTuberculosis (TB) is still considered a major global public
health problem, and Brazil is the 16th country in abso-
lute number of cases. Despite consistent advances achieved
with control measures, there are still major challenges to
face the growing resistance to anti-tuberculosis drugs in
several countries, including Brazil.1 Molecular epidemiology
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studies of M. tuberculosis have gained emphasis among clini-
cal researchers. New knowledge on the TB pathogenesis andnew control strategies.2,3 Recently, the World Health Organi-
zation set the Global “Stop TB Plan” to ﬁnd patients harboring
resistant strains of M.  tuberculosis. This initiative has been
e under the CC BY-NC-ND license. (http://creativecommons.org/
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mportant to test ﬁrst-line TB drugs and promoting research
o develop new drugs, vaccines, and diagnostic strategies.1,4
Among the techniques used, whole genomic sequencing
WGS) is worth mentioning, especially for the investigation of
acilli resistance. This approach enables accurate assessment
f mutations related to bacilli resistance to several TB drugs.
his information would allow the development of new diag-
ostic methods and therapeutic strategies applied for disease
ontrol.5
Outhred et al. advocate the use of WGS  for all multidrug-
esistant M.  tuberculosis isolates as an alternative plan to
mprove patient care, monitor for transmission events, and
ontribute to better understanding of resistance-associated
utations.6
This study describes a challenging case of treatment fail-
re of a patient under MDR-TB therapy and reports phenotypic
nd molecular drug resistance test results in correlation
o mutations identiﬁed with a whole genome sequencing
nalysis.
Three isolates of M.  tuberculosis from a single patient, dur-
ng different time points of his treatment, were evaluated
ased on phenotyping and genotyping testing: isolate 1 was
ollected before the patient started the follow-up in the ref-
rence center, when clinical and microbiological failure was
iagnosed, despite regular TB treatment with rifampicin (R),
soniazid (H), pyrazinamide (Z) and ethambutol (E); isolate 2
as collected in the ninth month of MDR-TB treatment (other
linical and microbiological failure); and isolate 3 was obtained
n the 13th month of MDR-TB treatment.
A nonradiometric phenotypic susceptibility testing was
erformed in liquid medium (MGIT 960; Becton Dickinson
iagnostic Systems, Sparks, MD)  for isolate 1. Besides this
usceptibility phenotypic testing, two line probe assays (LPA),
enotype MTBDRplus and MTBDRsl (Hain Lifescience, GmbH,
ermany), were performed in isolates 2 and 3. Genotype
TBDRplus evaluates the main mutations associated with
ifampicin (rpoB gene mutations) and isoniazid (katG e inhA
utations) resistance. Genotype MTBDRsl detects mutations
elated with resistance to ﬂuoroquinolones (gyrA gene muta-
ions), second-line injectable drugs (SLID) (rrs gene mutations)
nd ethambutol (embB gene mutations).7,8 Finally, the two
tored samples (isolates 2 and 3) were submitted to WGS  anal-
sis using Illumina MiSeq Sequecing System (Illumina, San
iego, CA, USA). LPAs and WGS  tests were performed with
tored isolates 2 and 3 at the end of the patient’s treatment.
herefore, this information was not available to the clinician
uring the treatment. Isolate 1 was not tested again because
t was not viable.
Generated reads with phred scale score superior to 30
as mapped with BWA v0.7.5a program (Burrows-Wheeler
lignment Tool) using the reference genome M.  tuberculosis
37Rv. Conversion from sequence alignment map  format to
orted, indexed BAM ﬁles was done using SAMtools (version
.1.19). PCR-duplicates were removed using the MarkDu-
licates option of the Picard software tools (version 1.61).
he variants were found according to the pipeline SAM-
ools/BCFtools v 0.1.18 and annotated with SnpEff v 4.0.
atabases TB Drug Resistance Mutation Database9 and M. tb Drug
esistance Directed Sequencing Database10 were used to identify
utations described for the TB bacilli. All detected mutations6;2 0(3):290–293 291
were conﬁrmed based on TB proﬁler online tool, described by Coll
et al.,11 to remove single nucleotide polymorphisms (SNPs) at
drug resistance loci which were historically misclassiﬁed as
drug resistance markers.
This project was approved by the Ethics and Research Com-
mittee of the Hospital of the Ribeirão Preto Medical School of
the University of São Paulo (protocol number: 944117 – Febru-
ary 1, 2015).
The patient was initially treated with RHZE for six months.
During the last month clinical and microbiological failure
(acid-fast smear positive and respiratory symptoms) was diag-
nosed. This M.  tuberculosis isolate showed R and H resistance
in the ﬁrst phenotypic susceptibility testing. The patient was
referred to the regional TB drug resistance center and his
treatment was switched to streptomycin (Sm), E, oﬂoxacin
(FQ), Z, and terizidone (Tz), following the Brazilian guide-
lines for the management of MDR-TB. During the ﬁrst nine
months of treatment, there was a transient improvement
followed by recurrence of symptoms. Sputum culture was col-
lected and the same MDR-TB treatment was maintained until
the 13th month. The therapy was empirically optimized by
adding ethionamide, extending the period of streptomycin
and increasing the local support for directly observed treat-
ment, while the results of phenotypic testing from isolate 3
were still pending. The treatment was successfully completed
after 24 months, with clinical and microbiological cure. After
that, instigated by this unusual and intriguing case and its
outcome, we decided to carry on molecular studies on the
patient’s isolates 2 and 3.
Isolate 1 showed resistance to R and H in the phenotypic
test. Phenotypic testing of isolate 2 showed resistance to these
two drugs and also to Z. The LPA of this isolate showed resis-
tance to R (lost wild type 8 and gained rpoB S450L mutation),
H (lost wild type and gained KatG S315T1 mutation), and E
(lost wild type 1 and gained embB M306V mutation). Isolate 3
showed resistance to R, I, E (same mutations described in iso-
late 2), and acquired a new resistance pattern to FQ (gyrA D94G
mutation) in the LPA test. Phenotypic testing of isolate 3, which
became available close to the end of the patient’s treatment,
showed resistance to the above mentioned drugs and also to
Z. The critical concentrations of Bactec-MGIT 960TM reported
by the manufacturer’s drug susceptibility testing (DST) proto-
col were as follows: H: 0.10 g/mL; R: 1.0 g/mL; EM: 5.0 g/mL;
Sm:  1.0 g/mL; Z: 100 g/mL; FQ (oﬂoxacin): 2 g/mL; Amikacin
1.0 g/mL; Capreomycin 2.5 g/mL. The susceptibility proﬁle
of isolates in the phenotypic test and LPA are described in
Table 1.
The WGS  analysis of these two strains generated the total
of 43,036,497 reads (28,171,267 for strain 1 and 14,865,230 for
strain 2), with an average coverage of 469× for the isolate 2
and 244× for the isolate 3. Bioinformatics analysis reported
11 mutations already described as associated with resistance
in isolate 2 and 12 mutations in isolate 3 (Table 2). Addi-
tional mutation in gyrA gene (D94G) was identiﬁed in isolate
3, which is one of the most frequent mutations associated
with resistance to FQ, and is tested by the LPA Genotype MTB-
DRsl. Although all mutations showed by LPA were validated
by WGS,  additional mutations were detected, including those
conferring resistance to other drugs despite bacilli susceptibil-
ity demonstrated in the phenotypic drug susceptibility testing
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Table 1 – Results of phenotypic and LPA tests: susceptibility proﬁle of tested drugs.
Isolate 1 detected resistance Isolate 2 detected resistance Isolate 3 detected resistance
Phenotypic drug susceptibility testing (DST) Rifampicin; Isoniazida Rifampicin; Isoniazid; Rifampicin; Isoniazid
Pyrazinamideb Oﬂoxacin; Pyrazinamide
Ethambutolc
Genotype MTBDRplus (R; H) NA Rifampicin Rifampicin
Isoniazid Isoniazid
Genotype MTBDRsl (E; FQ; SLID) NA Ethambutol Ethambutol
FQ
WGS NA Available (see Table 2) Available (see Table 2)
NA, not available; R, rifampicin; H, isoniazid; E, ethambutol; FQ, ﬂuoroquinolones; SLID, second line injectable drugs.
a Isolate 1 collected before MDR-TB treatment – susceptible to E and Sm. SLID not tested.
b Isolate 2 collected in the ninth month of MDR-TB treatment – susceptible to E, SLID and FQ.
c Isolate 3 collected on the 13th month of MDR-TB treatment – susceptible to Sm and SLID.














gyrA Fluoroquinolones 7362 E21Q Yes Yes G C Missense
gyrA Fluoroquinolones 7582 D94Ga No Yes A G Missense
rpoB Rifampicin 759939 P45T Yes Yes C A Missense
rpoB Rifampicin 761155 S450L Yes Yes C T Missense
rpsL Streptomycin 781395 – Yes Yes T C Promoter gene
tlyA Aminoglycosides 1917972 L11L Yes Yes A G Synonymous
katG Isoniazid 2154915 E399E Yes Yes A G Synonymous
katG Isoniazid 2155168 S315T Yes Yes G C Missense
pncA Pyrazinamide 2289039 W68L Yes Yes G T Missense
alr Cycloserine 3840719 L234L Yes Yes A G Synonymous
alr Cycloserine 3841403 E6D Yes Yes G T Missense
embB Ethambutol 4247429 M306V Yes Yes A G Missense
ing.
100% 
ra Mutation detected only in the isolate 3, by whole genomic sequenc
Except for mutation D94G, the SNPs reads for isolate 2 and 3 were 
(gyrA E21Q in isolate 2, rpsL promoter gene in genomic position
781395, tlyA L11L for isolates 2 and 3).
The relation between genome mutations and phenotypic
resistance is particularly important for therapeutic decision,
because different mutations can cause different resistance
proﬁles or not even cause any phenotypic resistance.12 Coll
et al. compiled a library of mutations predictive of drug resis-
tance, and removed phylogenetic SNPs at drug resistance
loci, which were historically misclassiﬁed as drug resistance
markers.11
WGS  has great application potential to detect bacilli resis-
tance in clinical practice. However, further work is needed to
determine additional resistance polymorphisms as it should
be noted that high positive predictive values are crucial for
drug resistance tests where the consequence of a false posi-
tive result may lead to unnecessary treatment and prolonged
patient isolation.11
The WGS  of M. tuberculosis is a great advance in the knowl-
edge of bacilli resistance, as well as in the clinical management
of TB. This technique presents greater discriminatory power,
enabling analysis of additional mutations, not possible to be
assessed by other methods. WGS  has the potential for clinical
use, as mentioned by other authors6,11–14 for fast and accu-
rate assessments in cases of illness caused by strains resistantidentical, with no signs of heteroresistance.
to multiple drugs, with an impact on therapeutic decisions.
However, this is a high-cost technology and it is still critical
to understand and standardize correlations between geno-
typic and phenotypic resistance to really optimize its clinical
use.
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